Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSH | P09668 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614462 | 0.87 | TFPI (0.46) | TFPIIL23RAPLNRC5AR1MC4R | |
| SCHEMBL29614491 | 0.87 | CTSL (0.46) | TFPIIL23RAPLNRGLP1RSCTR | |
| SCHEMBL29614488 | 0.87 | CTSL (0.46) | TFPIIL23RAPLNRGLP1RSCTR | |
| SCHEMBL31437150 | 0.85 | CTSL (0.47) | IL23RCTSLCTSSCTSKCTSH | |
| SCHEMBL29614438 | 0.84 | MC4R (0.46) | APLNRGLP1RSCTRC5AR1MC4R | |
| SCHEMBL31437155 | 0.83 | SLC15A2 (0.44) | APLNRC5AR1MC4RCTSLCTSS | |
| SCHEMBL21397756 | 0.82 | APLNR (0.47) | IL23RAPLNRMC4RCTSLCTSS | |
| SCHEMBL31032683 | 0.82 | GLP1R (0.51) | TFPIGLP1RSCTRC5AR1OPRL1 | |
| SCHEMBL31032668 | 0.82 | GLP1R (0.51) | TFPIGLP1RSCTRC5AR1OPRL1 | |
| SCHEMBL30655854 | 0.82 | GLP1R (0.53) | TFPIAPLNRGLP1RSCTRMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | TFPI 1747/4885IL23R 647/4885APLNR 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.